Stanford-Intermountain Fellow in Population Health and Health Services Research

Stanford Advisors

All Publications

  • Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19. Open forum infectious diseases Webb, B. J., Buckel, W., Vento, T., Butler, A. M., Grisel, N., Brown, S. M., Peltan, I. D., Spivak, E. S., Shah, M., Sakata, T., Wallin, A., Stenehjem, E., Poulsen, G., Bledsoe, J. 2021; 8 (7): ofab331


    Background: Neutralizing monoclonal antibodies (MAbs) are a promising therapy for early coronavirus disease 2019 (COVID-19), but their effectiveness has not been confirmed in a real-world setting.Methods: In this quasi-experimental pre-/postimplementation study, we estimated the effectiveness of MAb treatment within 7 days of symptom onset in high-risk ambulatory adults with COVID-19. The primary outcome was a composite of emergency department visits or hospitalizations within 14 days of positive test. Secondary outcomes included adverse events and 14-day mortality. The average treatment effect in the treated for MAb therapy was estimated using inverse probability of treatment weighting and the impact of MAb implementation using propensity-weighted interrupted time series analysis.Results: Pre-implementation (July-November 2020), 7404 qualifying patients were identified. Postimplementation (December 2020-January 2021), 594 patients received MAb treatment and 5536 did not. The primary outcome occurred in 75 (12.6%) MAb recipients, 1018 (18.4%) contemporaneous controls, and 1525 (20.6%) historical controls. MAb treatment was associated with decreased likelihood of emergency care or hospitalization (odds ratio, 0.69; 95% CI, 0.60-0.79). After implementation, the weighted probability that a given patient would require an emergency department visit or hospitalization decreased significantly (0.7% per day; 95% CI, 0.03%-0.10%). Mortality was 0.2% (n = 1) in the MAb group compared with 1.0% (n = 71) and 1.0% (n = 57) in pre- and postimplementation controls, respectively. Adverse events occurred in 7 (1.2%); 2 (0.3%) were considered serious.Conclusions: MAb treatment of high-risk ambulatory patients with early COVID-19 was well tolerated and likely effective at preventing the need for subsequent emergency department or hospital care.

    View details for DOI 10.1093/ofid/ofab331

    View details for PubMedID 34327256

  • The MAb Squad: Delivering Covid-19 Monoclonal Antibody Therapy Across a Large Geographic Region NEJM Catalyst Sakata, T., Brunisholz, K. D., Andersen, C., Davie, D., Srivastava, R., Webb, B. 2021

    View details for DOI 10.1056/CAT.21.0154